Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Aug;19(8):384-9.
doi: 10.1023/a:1016398405248.

Effect of in vivo GnRH agonist and GnRH antagonist on hCG and insulin-stimulated progesterone production by human granulosa-lutein cells in vitro

Mohamed F M Mitwally  1 , Robert F Casper
Affiliations
Clinical Trial

Effect of in vivo GnRH agonist and GnRH antagonist on hCG and insulin-stimulated progesterone production by human granulosa-lutein cells in vitro

Mohamed F M Mitwally et al. J Assist Reprod Genet. 2002 Aug.

Abstract

Purpose: To investigate hCG and insulin-stimulated progesterone (P) production by human granulosa-lutein cells (hGLC) in vitro.

Methods: hGLCs were isolated from patients undergoing IVF-ET cycles in which GnRH agonist or GnRH antagonist was used to prevent a midcycle gonadotropin surge. The cells were cultured for 3 days, and then treated with hCG 0.5, 1, and 10 IU/I, and insulin 0.01, 0.1, and 1 microM in serum free conditions. In vitro P production was measured by enzyme immunoassay.

Results: hCG stimulated P production by hGLCs from cycles in which GnRH antagonist was used, but a blunted response was seen in GnRH-agonist treated cycles. Insulin-stimulated P production was similar in cells from cycles in which GnRH-agonist or GnRH-antagonist treatment was used.

Conclusions: Because insulin and hCG may share common pathways beyond the level of receptor activation, we hypothesize that GnRH agonist, but not GnRH antagonist, may affect the expression and/or activation of LH receptors in the hGLCs.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Hughes EG, Fedorkow DM, Daya S, Sagle MA, van de Koppel P, Collins JA. The routine use of gonadotropinreleasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: A meta-analysis of randomized controlled trials. Fertil Steril. 1992;58:888–896. - PubMed
    1. Diedrich K, Diedrich C, Santos E, Bauer O, Zoll C, AI-Hasani S, Reissman T, Krebs D, Klingmuller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophinreleasing hormone antagonist cetrorelix during ovarian stimulation. Hum Reprod. 1994;9:788–791. - PubMed
    1. Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF, Pavlonz SN. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: Cycle performance and in vitro steroidogenesis of granulosa lutein cells. AmJ Obstet Gynecol. 1995;172:1518–1525. - PubMed
    1. Felberbaum RE, Reissmann T, KuÈ pker W, Bauer O, AI-Hasani S, Diedrich C, Diedrich K. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. Eur J Obstet Gynecol Reprod Biol. 1995;61:151–155. - PubMed
    1. Felberbaum R, Reissmann T, KuÈ pker W, AI-Hasani S, Bauer O, Schill T, Zoll C, Diedrich C, Diedrich K. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist cetrorelix at different dosages. J Assist Reprod Genet. 1996;13:216–222. - PubMed

Publication types

MeSH terms